A single particle a thousand times thinner than a human hair may not sound like the future of cancer care. Yet the same class of microscopic carriers that delivered the mRNA behind COVID-19 vaccines is now steering some of the most closely watched trials in oncology, gene editing and precision imaging. Nanoparticles have quietly moved from the laboratory bench to the pharmacy shelf, and the pace is accelerating.
Broadly, a nanoparticle is any engineered structure between roughly one and one hundred nanometres across. At that scale, materials behave differently than they do in bulk, and biology treats them differently too. A drug packaged inside the right nanoparticle can slip past barriers that would destroy it, linger in the bloodstream longer, and accumulate where it is needed rather than flooding the whole body. The U.S. National Cancer Institute keeps a running overview of how these tools are being applied across cancer nanotechnology, and the list of approved products now runs well past fifty.
Why size changes everything
The appeal of nanomedicine comes down to control. Conventional chemotherapy is famously indiscriminate: it attacks fast-dividing cells wherever it finds them, which is why hair loss, nausea and immune suppression are so common. Wrap that same drug inside a nanoparticle and you gain a steering wheel. Engineers can tune the particle’s surface, charge and size so that it circulates quietly until it reaches a tumour, then releases its payload close to the target.
Solid tumours also help by accident. Their blood vessels tend to be leaky and their drainage poor, so particles of the right dimensions tend to seep in and stay put, a quirk researchers call the enhanced permeability and retention effect. Add a targeting molecule to the surface, and the particle can seek out receptors that appear on cancer cells more than on healthy ones. The result, in principle, is more drug where the disease is and less everywhere else.
From pandemic vaccines to personalised cancer shots
No nanoparticle has had a bigger public moment than the lipid nanoparticle, or LNP. These fatty spheres were the unsung workhorse of the mRNA vaccines rolled out during the pandemic, shielding a fragile strand of genetic instructions long enough to reach human cells. That success turned LNPs into one of the hottest platforms in drug development.
The most striking application now in trials is the personalised cancer vaccine. Researchers sequence a patient’s tumour, identify the mutations that make it unique, and encode those targets into mRNA carried by lipid nanoparticles. Injected back into the patient, the vaccine trains the immune system to hunt cells bearing those specific flags. Melanoma has produced the most encouraging early data, and studies are extending the approach to lung and other solid tumours. It is a strategy that would have been science fiction a decade ago, built on infrastructure the pandemic forced the world to perfect.
Targeting tumours while sparing healthy tissue
Long before mRNA, nanoparticles were already reshaping chemotherapy. Doxil, a liposomal form of the drug doxorubicin, became the first nanomedicine cleared by regulators back in the 1990s, and it is still in use because the packaging blunts the drug’s damage to the heart. A whole family of liposomal cancer drugs followed, each trying to widen the gap between effect and side effect.
| Nanomedicine | Encapsulated drug | Main use |
|---|---|---|
| Doxil | Doxorubicin | Ovarian cancer, myeloma |
| Onivyde | Irinotecan | Pancreatic cancer |
| Marqibo | Vincristine | Acute lymphoblastic leukaemia |
| DaunoXome | Daunorubicin | Kaposi sarcoma |
| Myocet | Doxorubicin | Metastatic breast cancer |
The commercial stakes match the clinical ones. The market for liposomal cancer therapeutics alone was valued at roughly 3.7 billion US dollars in 2021 and is expected to approach 7 billion by 2027, according to industry analysts. That growth is one reason the field keeps attracting both pharmaceutical giants and a long tail of biotech start-ups. For a wider view of how these tools fit into the broader field, our overview of nanotechnology in medicine traces the same story across diagnostics and regenerative therapies.
Gene editing, imaging and the next frontier
Delivery is the quiet bottleneck of gene therapy, and nanoparticles are increasingly the answer. In vivo CRISPR treatments, which edit genes inside the body rather than in a dish, rely on lipid nanoparticles to ferry the editing machinery to the liver, where it can correct the instructions behind inherited disorders. Early programmes targeting rare metabolic and blood conditions have shown that a carefully engineered particle can carry a gene-editing tool to exactly the tissue that needs it.
Metals bring their own tricks. Gold nanoparticles can be tuned to absorb light and heat, opening the door to therapies that cook tumours from within or light them up for surgeons. Iron-oxide particles respond to magnetic fields, which makes them useful both as contrast agents in imaging and as beacons that mark the fuzzy border of a tumour during an operation. Researchers are even testing particles designed to slip past the blood-brain barrier, one of the most stubborn obstacles in treating brain cancer. The same appetite for precision is driving neighbouring fields, from the brain-computer interfaces now entering human trials to the enormous computing clusters that speed up the molecular design behind these particles.
A market growing as fast as the science
Put the pieces together and nanomedicine has become one of the fastest-expanding corners of healthcare. Analyst estimates for the total market in 2025 range widely, from around 230 billion to well over 370 billion US dollars depending on how the category is defined, but they agree on direction: most forecasts see the sector more than doubling over the next decade, with annual growth rates in the low-to-mid teens. Gene-therapy delivery, powered largely by lipid nanoparticles, is expanding faster still.
The obstacles are real. Manufacturing nanoparticles at scale, with the same quality batch after batch, remains difficult and expensive. Regulators are still refining how to evaluate products that behave unlike ordinary drugs. And questions about long-term safety and how the body clears these materials will only grow as more particles enter clinical use. None of that has slowed the momentum. If the past five years belonged to the vaccine, the next five may belong to the far broader promise of medicine delivered one nanoparticle at a time.
Frequently asked questions
What exactly is a nanoparticle in medicine?
It is an engineered particle, usually between one and one hundred nanometres wide, built to carry a drug, a piece of genetic material or an imaging agent to a specific place in the body. The particle protects its cargo and helps control where and when it is released.
Are nanoparticle medicines already approved?
Yes. More than fifty nanomedicines have been approved by the U.S. FDA, covering cancer, infectious disease and other conditions. Familiar examples include liposomal chemotherapy drugs and the lipid nanoparticles used in mRNA vaccines.
How do nanoparticles reduce side effects?
By keeping a drug packaged until it reaches its target, nanoparticles limit how much of it reaches healthy tissue. That can reduce the collateral damage that makes treatments such as chemotherapy so hard to tolerate.
What is the biggest challenge ahead?
Manufacturing consistency, cost and long-term safety are the main hurdles. Making identical particles at industrial scale is technically demanding, and researchers are still studying how the body handles them over time.
